Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $2.4 million.

  • Intellia Therapeutics' Depreciation & Amortization (CF) fell 769.23% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year decrease of 216.62%. This contributed to the annual value of $10.3 million for FY2024, which is 1444.44% up from last year.
  • Intellia Therapeutics' Depreciation & Amortization (CF) amounted to $2.4 million in Q3 2025, which was down 769.23% from $2.5 million recorded in Q2 2025.
  • Over the past 5 years, Intellia Therapeutics' Depreciation & Amortization (CF) peaked at $2.6 million during Q2 2024, and registered a low of $1.6 million during Q1 2021.
  • For the 5-year period, Intellia Therapeutics' Depreciation & Amortization (CF) averaged around $2.2 million, with its median value being $2.2 million (2023).
  • Per our database at Business Quant, Intellia Therapeutics' Depreciation & Amortization (CF) surged by 2253.66% in 2024 and then crashed by 769.23% in 2025.
  • Intellia Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $1.9 million in 2021, then grew by 9.0% to $2.1 million in 2022, then grew by 20.93% to $2.5 million in 2023, then grew by 3.65% to $2.6 million in 2024, then dropped by 7.01% to $2.4 million in 2025.
  • Its Depreciation & Amortization (CF) was $2.4 million in Q3 2025, compared to $2.5 million in Q2 2025 and $2.5 million in Q1 2025.